Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RO 7297089

Next Previous
Drug Profile

RO 7297089

Alternative Names: AFM-26; RG 6296; RO-7297089

Latest Information Update: 16 Jun 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affimed Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma

Most Recent Events

  • 16 Feb 2022 Genentech competes a phase I trial in Multiple myeloma in Australia, Belgium, Denmark and Norway (IV) (NCT04434469)
  • 11 Dec 2021 Interim efficacy, pharmacokinetics, pharmacodynamics and adverse events data from the phase I trial in multiple myeloma presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
  • 03 Nov 2021 Genetech completed enrolment in the phase I trial for Multiple myeloma (Second-line therapy or greater) in Belgium, Denmark, Australia and Norway (IV) (NCT04434469)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top